NTLA
Intellia Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.58
+1.40%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 24.42x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 2.23x
- Price / sales
- 27.27x
- Price / cash flow
- -4.68x
Enterprise value
- Enterprise value
- $1.3B
- EV / sales
- 21.15x
- EV / EBITDA
- -3.22x
- EV / EBIT
- -2.97x
- Market cap
- $1.6B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026